Wockhardt Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Small Cap

Ion Exchange (India) Ltd, Indo Count Industries Ltd, Emami Ltd and Sharda Cropchem Ltd are among the other gainers in the BSE's 'A' group today, 01 July 2024.

Wockhardt Ltd soared 17.95% to Rs 809.6 at 11:47 IST. The stock was the biggest gainer in the BSE's 'A' group. On the BSE, 2.89 lakh shares were traded on the counter so far as against the average daily volumes of 52857 shares in the past one month.

Ion Exchange (India) Ltd spiked 13.62% to Rs 653.45. The stock was the second biggest gainer in 'A' group. On the BSE, 3.05 lakh shares were traded on the counter so far as against the average daily volumes of 36729 shares in the past one month.

Indo Count Industries Ltd surged 12.76% to Rs 439.75. The stock was the third biggest gainer in 'A' group. On the BSE, 3.65 lakh shares were traded on the counter so far as against the average daily volumes of 28281 shares in the past one month.

Emami Ltd jumped 10.70% to Rs 762.8. The stock was the fourth biggest gainer in 'A' group. On the BSE, 1.76 lakh shares were traded on the counter so far as against the average daily volumes of 54522 shares in the past one month.

Sharda Cropchem Ltd rose 9.56% to Rs 489.3. The stock was the fifth biggest gainer in 'A' group. On the BSE, 85117 shares were traded on the counter so far as against the average daily volumes of 17304 shares in the past one month.

Powered by Capital Market - Live News

A young cancer patient with a chronic thigh infection caused by a very resistant bacteria was successfully treated with an investigational antibiotic called Zaynich. The patient had been in the hospital for nearly 9 months and tried many other antibiotics before this. After 4 weeks of Zaynich, the wounds healed and the patient was able to resume chemotherapy. This is the first time Zaynich has been used in the US to treat this type of infection.

Moreover, Zaynich received a very high susceptibility breakpoint (64 mg/L) from Clinical and Laboratory Standards Institute (CLSI), indicating its effectiveness against a broad range of highly resistant gram-negative bacteria. This is the first time ever an antibiotic gets such a high breakpoint for all three major gram-negative families (Enterobacterales, Pseudomonas, and Acinetobacter). Zaynich has shown promising results in treating critically ill patients with infections resistant to other antibiotics in compassionate use programs. This high breakpoint is based on over 8 years of research data and could pave the way for wider use of Zaynich upon formal approval.

Zaynich (Zidebactam/Cefepime-WCK 5222) is currently undergoing a global Phase 3 trial to potentially be approved for sale worldwide. Earlier US studies included safety and effectiveness testing.

Wockhardt is a global pharmaceutical company focused on developing new antibiotics to fight superbugs. They are unique in having 6 antibiotic programs designated by the USFDA as Qualified Infectious Disease Products. With a large research team and international presence, they develop and manufacture drugs across the globe.

On a consoldiatd basis, Wockhardt reported net loss of Rs 169 crore in Q4 March 2024 as against net loss of Rs 208 crore in Q4 March 2023. Net sales rose 3.24% YoY to Rs 700 crore in Q4 March 2024.

Powered by Capital Market - Live News

Wockhardt announced that the Annual General Meeting (AGM) of the company will be held on 28 June 2024.

Powered by Capital Market - Live News

Net Loss of Wockhardt reported to Rs 169.00 crore in the quarter ended March 2024 as against net loss of Rs 208.00 crore during the previous quarter ended March 2023. Sales rose 3.24% to Rs 700.00 crore in the quarter ended March 2024 as against Rs 678.00 crore during the previous quarter ended March 2023.

For the full year,net loss reported to Rs 463.00 crore in the year ended March 2024 as against net loss of Rs 559.00 crore during the previous year ended March 2023. Sales rose 5.55% to Rs 2798.00 crore in the year ended March 2024 as against Rs 2651.00 crore during the previous year ended March 2023.

Powered by Capital Market - Live News